Clinical trial
A Randomized, Double-blind, Placebo-Controlled, Cross-Over Trial to Investigate the Effect of GSK189075 on Cardiac Repolarization as Compared to Placebo and a Single Dose of Moxifloxacin in Healthy Adult Subjects
NCT00532610 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-Controlled, Cross-Over Trial to Investigate the Effect of GSK189075 on Cardiac Repolarization as Compared to Placebo and a Single Dose of Moxifloxacin in Healthy Adult Subjects
- Lead sponsor
- GlaxoSmithKline
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- September 30, 2007
- Completion date
- February 29, 2008
- Enrollment
- 78 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
diabetes mellitus, type 2, type 2 diabetes mellitus